InvestorsHub Logo
icon url

gdollasign

09/14/10 1:22 PM

#1876 RE: BTH #1875

Because it is 100% MRK responsibility to present Rida. You know that already though.....so why the question?

G
icon url

ampakine

09/14/10 1:49 PM

#1879 RE: BTH #1875

Unsolicited response to BioTechHedge's rhetorical "question":

OK, let's go for the obvious:

Cause 534 is a huge, most likely blockbuster, massively value enhancing product, VS Rida, which is now owned by Merck, and is a much more modest (but still very important) revenue source.

Rida pays for the rent and electricity and bunsen burners while Ariad moves 534 toward FDA approval.
icon url

Bxofscidad

09/14/10 10:09 PM

#1891 RE: BTH #1875



For two reasons:


1- We own 100% of 534 and only have a % of sales of Rida.


2- 534 is at the stage that the all important pivotal trial is starting and much info on the design, prospects of success and market must be divulged to the shareholders, while Rida is at the stage that, with one exception, nothing new will happen for about three months (till the final results will be reported on). In addition, it may very well be possible that Merck will take the lead in reporting Rida progress (which might be part of the new agreement between Merck and Ariad). The one exception alluded to, is that by the end of this month, at a International Scientific Meeting, results of the Rida Endometrial Phase 11 trial will be reported on.

JMHO, Barry